ENT Disorder Treatment Market Research, 2031
The global ENT Disorder Treatment Market size was valued at $2.4 billion in 2021, and is projected to reach $4.5 billion by 2031, growing at a CAGR of 6.5% from 2022 to 2031. ENT stands for ears, nose, and throat in the human body; these are interconnected to each other.. Ear, nose and throat are vital parts of the body, ears are the sensory organ that is responsible to hear sounds, and maintaining the overall balance of the body. Nose is another type of sensory organ which help to smell, it also works as a defense mechanism restricting the entry of foreign particles, whereas, the throat provides the passage for air, water and food. ENT treatment includes medical and surgical management & treatment of diseases such as cold, esophagus disorders, tonsillitis, and others. ENT disorders are mainly handled by an otolaryngologist. Malfunction in any of these organs due to various diseases can directly affect the quality of the life. Some of the common types of ENT disorders are ear infections, sinus infections, tonsilitis, acoustic neuroma, Meniere’s disorder, and others. The ENT disorder treatment consists of a wide range of drugs such as nasal decongestion sprays, oral and topical antihistamines, nasal steroids, and nasal saline washes are available. In addition, a variety of medications are readily available to treat ear infections, and a number of medical devices are also available to treat presbycusis.
The key factors that drive the ENT Disorder Treatment Market growth are rapid changes in environmental conditions, increase in the level of air and noise pollution and rise in geriatric population. As geriatric population is susceptible to get infection easily due to poor immune systems which further propels the growth of the market. For instance, according to the report published by the technical group on population projections for India, States that about 138 million are aged above 60 in India in 2021 and this is further expected to increase in 2031. Thus, increase in the geriatric population has increased the demand for antibiotics to treat nasal, ear & throat infections which drives the growth of market.
Moreover, rise in the prevalence of sinusitis and chronic rhinitis across the world further drives the growth of the market. In addition, rise in healthcare expenditure and increase in government initiatives in developing countries are the key factors which further boost the market growth. However, high cost of medical devices and surgeries for sinusitis and tonsillitis hamper the market growth. Conversely, emerging healthcare market in developing countries is expected to provide an ENT Disorder Treatment Market opportunity during the forecast period.
The global ENT Disorder Treatment Market size was valued at $2.4 billion in 2021, and is projected to reach $4.5 billion by 2031, growing at a CAGR of 6.5% from 2022 to 2031. The ENT disorder treatment market is segmented on the basis of drug type, organ, end user and region. By drug type it is segmented into antibiotics, anti-inflammatory and others. By organ, it is segmented into ear, nose and throat. By end user the market is segmented into hospitals and clinics, homecare settings and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Drug Type Segment review
By drug type, ENT Industry is segmented into antibiotics, anti-inflammatory and others. The antibiotics segment accounted for the largest share of the market. The dominance of this segment can be attributed to rise in number of ENT diseases which is increasing due to increase in air and noise pollution as well as bacterial concentration in the environment leading to various infections such as sinusitis, and chronic rhinitis infection. Hence, propels the growth of the ENT disorder treatment market for antibiotics.
The anti-inflammatory segment is anticipated to grow at a significant rate during the forecast period. The need for anti-inflammatory medications has increased globally due to the rising geriatric population suffering from acute and chronic infectious illnesses, which is fueling the growth of the market.
Organ Segment Review
By organ, the ENT disorder treatment market is segmented into ear, nose and throat. The nose segment was the highest revenue contributor to the market, owing to the rise in the prevalence of allergic rhinitis and the increase in the prevalence of viral infection across the world drives the growth of the market.
The throat segment is expected to grow at a considerable growth rate during the ENT disorder treatment market. The increase in the prevalence of viral infection which causes sore-throat and irritation, and the rise in the prevalence of upper respiratory infection is the major factor contributing to the growth of the market.
End User Segment Review
By end user, the market is categorized into hospitals & clinics, homecare settings and others. The hospitals and clinics segment was the highest revenue contributor to the market. The increase in the prevalence of infectious and allergic disorders such as sinusitis, tonsillitis, ear infection, nasal airway obstruction, and an increase in the number of ENT patients visiting hospitals propels the growth of the market. The homecare settings segment is expected to grow at a considerable growth rate during the ENT disorder treatment market.
Region Segment Review
Region-wise, the ENT disorder treatment market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a majority of the ENT disorder treatment market share in 2021 and is anticipated to remain dominant during the forecast period. The increase in demand for antibiotics to treat allergic conditions like sinusitis, tonsillitis, cholesteatoma, and ear infections and the rise in R&D facilities for the approval and development of novel antibiotic therapies propel the growth of the market.
Asia-Pacific is anticipated to witness lucrative growth, owing to the rise in population in emerging countries like China, India, and Japan, increase in pollution, and surge in prevalence of infectious and allergic conditions.
The key players that operate in the ENT disorder treatment market are Sanofi, Novartis, GSK, Pfizer, Vitaris, Sun Pharma, AstraZeneca, Cipla, AurbindoPharma, Teva Pharmaceuticals, Bayer AG, Amneal Pharmaceuticals Ltd, M.M Pharma, Lyra Therapeutics, Lannet Company Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ent disorder treatment market analysis from 2021 to 2031 to identify the prevailing ent disorder treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the ent disorder treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global ent disorder treatment market trends, key players, market segments, application areas, and market growth strategies.
ENT Disorder Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 4.5 billion |
 Growth Rate | CAGR of 6.5% |
 Forecast period | 2021 - 2031 |
 Report Pages | 334 |
 By Drug Type |
|
 By Organ |
|
 By End User |
|
 By Region |
|
 Key Market Players | Aurbindo pharma, Teva Pharmaceuticals, Bayer Ag, Akira Healthcare, Astrazenca Plc, Mylan N.V., Amneal Pharmceuticals Ltd, Sanofi, Novartis, Pfizer Inc, Glaxosmithkline plc |
Analyst Review
This section provides various opinions of top-level CXOs in the ENT disorder treatment market. In accordance to several interviews conducted, the ENT disorder treatment market is expected to witness a significant growth in the future, owing to rise in geriatric population and increase in prevalence of infectious disease such as ear infection, nasal congestion, allergic conditions (sinusitis, tonsillitis and various others).
According to the perspectives of CXOs, global ENT disorder treatment market is expected to witness a steady growth in the future. Rise in geriatric population and surge in healthcare expenditure are the key factors driving the growth of the market. In addition, rise in technological advancement and increase in number of key players engaged in development of ENT drugs further propel the growth of the market. However, side effects associated with drugs are expected to hamper the growth of the market during the forecast period.
On the contrary, rise in demand for such devices and increase in economies of developing countries are expected to provide opportunities for the growth of the global ENT disorder treatment market in future.
Further, North America is expected to witness highest growth, in terms of revenue, owing to advanced healthcare facilities provided by government and private authorities, and rise in R&D facilities for the approval and development of novel antibiotic therapies in the region.
Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to increase in geriatric population and high level of pollution which causes ENT related disorders
The upcoming trends are rapid changes in environmental conditions and the increase in the level of air and noise pollution and rise in geriatric population. As geriatric population is more susceptible to get infected easily due to poor immune system which further propels the growth of the market.
The forecast period in the report is from 2022 to 2031
North America is the largest regional market for ENT Disorder Treatment
The market value of the ENT Disorder Treatment market in 2021 was $2370.59 Million
Sanofi, Novartis, GSK, Pfizer, Vitaris, Sun Pharma, AstraZeneca, Cipla are the top companies to hold the market share in ENT Disorder Treatment
The base year for the report is 2021
No, value chain analysis is provided in the ENT Disorder Treatment market report
Yes, companies are profiled in ENT Disorder Treatment market the report
Loading Table Of Content...
